Introduction to generic nintedanib for the treatment of pulmonary fibrosis

Nintedanib (Nintedanib) is a broad-spectrum tyrosine kinase inhibitor that is widely used to treat idiopathic pulmonary fibrosis (IPF) and a variety of lung lesions related to interstitial lung diseases, especially chronic progressive pulmonary fibrosis and pulmonary fibrosis related to systemic sclerosis.

As an innovative targeted drug developed by the company, nintedanib effectively delays the progression of pulmonary fibrosis by inhibiting the signaling of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) receptors. With the gradual expansion of its clinical application, multiple versions of generic drugs have begun to appear on the market to meet the needs of patients in different countries for affordable treatment.

Globally, generic drugs of nintedanib are mainly concentrated in India, Laos and other emerging drug-producing countries. Although the price of these generic drugs is much lower than that of the original drugs, their active ingredients are highly consistent with the original products and are theoretically similar in efficacy and safety.

Currently common generic drug manufacturers include IndiaBDR Pharmaceuticals, India's Grammark Pharmaceuticals, and Laos' ASEAN Pharmaceuticals. Among them, Indian company BDR enjoys a high reputation in the field of generic drugs, and its generic nintedanib products are used in many low- and middle-income countries to support the long-term treatment of patients. Grandmark relies on its relatively strict quality control system to obtain approval for its generic drugs from many countries and regions. ASEAN Pharmaceuticals has a particularly obvious price advantage. The price of its generic drugs is about RMB 600, which is far lower than the market price of original drugs. It undoubtedly provides more choices for patients with limited financial conditions.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib